BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy.
The study found that patients experienced sustained quality of life up to 3 months after treatment. The company called the study of its novel data collection tool the “the first-of-its-kind” in interventional oncology.
Get the full story at our sister site, Drug Delivery Business News.